LTPA2017043I1 - Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas - Google Patents

Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas

Info

Publication number
LTPA2017043I1
LTPA2017043I1 LTPA2017043C LTPA2017043C LTPA2017043I1 LT PA2017043 I1 LTPA2017043 I1 LT PA2017043I1 LT PA2017043 C LTPA2017043 C LT PA2017043C LT PA2017043 C LTPA2017043 C LT PA2017043C LT PA2017043 I1 LTPA2017043 I1 LT PA2017043I1
Authority
LT
Lithuania
Prior art keywords
human
therapeutic
antibodies specific
disclosed
diagnostic use
Prior art date
Application number
LTPA2017043C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Ucb Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma, S.A. filed Critical Ucb Pharma, S.A.
Publication of LTPA2017043I1 publication Critical patent/LTPA2017043I1/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTPA2017043C 2002-05-02 2017-12-21 Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas LTPA2017043I1 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Publications (1)

Publication Number Publication Date
LTPA2017043I1 true LTPA2017043I1 (lt) 2018-01-10

Family

ID=9935990

Family Applications (2)

Application Number Title Priority Date Filing Date
LTPA2017043C LTPA2017043I1 (lt) 2002-05-02 2017-12-21 Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
LTPA2017044C LTC1504035I2 (lt) 2002-05-02 2017-12-21 Antikūnai, specifiški žmogaus cd22, ir jų terapinis bei diagnostinis panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2017044C LTC1504035I2 (lt) 2002-05-02 2017-12-21 Antikūnai, specifiški žmogaus cd22, ir jų terapinis bei diagnostinis panaudojimas

Country Status (34)

Country Link
US (8) US7355011B2 (enExample)
EP (1) EP1504035B9 (enExample)
JP (3) JP4486494B2 (enExample)
KR (3) KR101386376B1 (enExample)
CN (3) CN103172742B (enExample)
AT (1) ATE462729T3 (enExample)
AU (1) AU2003223007C1 (enExample)
BE (1) BE2017C068I2 (enExample)
CA (1) CA2484420C (enExample)
CO (1) CO5631451A2 (enExample)
CY (3) CY1110134T1 (enExample)
DE (1) DE60331910D1 (enExample)
DK (1) DK1504035T6 (enExample)
EC (1) ECSP045470A (enExample)
ES (1) ES2341708T7 (enExample)
FR (1) FR17C1062I2 (enExample)
GB (1) GB0210121D0 (enExample)
HU (2) HUS1700056I1 (enExample)
IL (1) IL164923A (enExample)
LT (2) LTPA2017043I1 (enExample)
LU (2) LUC00058I2 (enExample)
MX (1) MXPA04010787A (enExample)
NL (1) NL300920I2 (enExample)
NO (3) NO336201B1 (enExample)
NZ (1) NZ536757A (enExample)
PL (1) PL218433B1 (enExample)
PT (1) PT1504035E (enExample)
RU (1) RU2342401C2 (enExample)
SG (1) SG161744A1 (enExample)
SI (1) SI1504035T1 (enExample)
TW (1) TWI324161B (enExample)
UA (1) UA92580C2 (enExample)
WO (1) WO2003093320A2 (enExample)
ZA (1) ZA200408851B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
CA2476776A1 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
HUE057124T2 (hu) 2002-05-02 2022-04-28 Wyeth Holdings Llc Calicheamicin származék - hordozó konjugátumok
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AR052774A1 (es) * 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RS54163B1 (sr) 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
BRPI0717902A2 (pt) * 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
AU2013251482B2 (en) * 2012-04-26 2018-01-04 Bioatla Llc Anti-CD22 antibodies
MY171473A (en) 2012-07-03 2019-10-15 Univ Washington Antibodies to tau
RU2015105588A (ru) 2012-07-19 2016-09-10 Редвуд Байосайнс, Инк. Антитело, специфическое к cd22, и способы его применения
AU2013335180B2 (en) 2012-10-24 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
PT3280729T (pt) * 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
SG11202009525VA (en) 2018-03-30 2020-10-29 Eureka Therapeutics Inc Constructs targeting cd22 and uses thereof
KR20220163962A (ko) * 2020-04-02 2022-12-12 난징 아이에이에스오 바이오테라퓨틱스 컴퍼니, 리미티드 완전 인간 항-인간 cd22 키메라 항원 수용체 및 그의 용도
US20230331840A1 (en) * 2020-08-27 2023-10-19 Fapon Biotherapy Inc. Cd22 antibody and application thereof
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
IL311090A (en) * 2021-08-27 2024-04-01 Peptron Inc Novel anti-muc1 antibody and use thereof
CN116217727B (zh) * 2021-12-06 2025-04-29 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8221191A (en) * 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
ATE247168T1 (de) * 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2182013C (en) 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
MX9701075A (es) 1994-08-12 1998-03-31 Myriad Genetics Inc Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
IL114909A (en) * 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) * 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
HK1046635B (en) * 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN1382259A (zh) * 1999-10-12 2002-11-27 康奈科斯优化研究和发展有限公司 检测粪便中抗酸微生物的改进方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2415100A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceutical Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
HUE057124T2 (hu) * 2002-05-02 2022-04-28 Wyeth Holdings Llc Calicheamicin származék - hordozó konjugátumok
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
AU2003223007C1 (en) 2019-08-08
CN101134779A (zh) 2008-03-05
RU2342401C2 (ru) 2008-12-27
CO5631451A2 (es) 2006-04-28
HK1186479A1 (zh) 2014-03-14
CN103172742A (zh) 2013-06-26
US7919606B2 (en) 2011-04-05
WO2003093320A3 (en) 2004-02-05
CY1110134T1 (el) 2015-01-14
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
SI1504035T1 (sl) 2010-07-30
LUC00058I1 (enExample) 2017-12-27
LUC00058I2 (enExample) 2018-02-26
HK1071762A1 (en) 2005-07-29
KR101238970B1 (ko) 2013-03-04
US20170145114A1 (en) 2017-05-25
FR17C1062I1 (enExample) 2018-02-16
LUC00057I1 (enExample) 2017-12-27
US7355011B2 (en) 2008-04-08
BE2017C068I2 (enExample) 2022-08-09
ZA200408851B (en) 2006-01-25
US20210371547A1 (en) 2021-12-02
DK1504035T6 (en) 2018-03-12
NO2017069I1 (no) 2017-12-21
US20100021995A1 (en) 2010-01-28
CA2484420C (en) 2014-09-16
PL373277A1 (en) 2005-08-22
KR101386376B1 (ko) 2014-04-16
IL164923A (en) 2012-03-29
JP2010022372A (ja) 2010-02-04
PT1504035E (pt) 2010-06-07
JP5920934B2 (ja) 2016-05-18
UA92580C2 (ru) 2010-11-25
NL300920I2 (nl) 2021-04-15
DK1504035T3 (da) 2010-06-07
FR17C1062I2 (fr) 2020-05-29
US20120302739A1 (en) 2012-11-29
ATE462729T3 (de) 2010-04-15
RU2004135103A (ru) 2005-10-27
CN101134779B (zh) 2013-03-13
CN100384878C (zh) 2008-04-30
ES2341708T7 (es) 2018-04-11
KR20110004463A (ko) 2011-01-13
AU2003223007B2 (en) 2009-07-16
LTC1504035I2 (lt) 2022-04-11
CA2484420A1 (en) 2003-11-13
TWI324161B (en) 2010-05-01
NO336201B1 (no) 2015-06-15
CN1662558A (zh) 2005-08-31
CN103172742B (zh) 2016-05-11
US20160326247A1 (en) 2016-11-10
CY2017045I2 (el) 2019-11-27
EP1504035B9 (en) 2018-10-17
US8895714B2 (en) 2014-11-25
HUS1700056I1 (hu) 2018-07-30
CY2017046I1 (el) 2018-12-12
TW200307690A (en) 2003-12-16
KR20050025167A (ko) 2005-03-11
US20110165659A1 (en) 2011-07-07
JP4486494B2 (ja) 2010-06-23
AU2003223007A1 (en) 2003-11-17
PL218433B1 (pl) 2014-12-31
ES2341708T3 (es) 2010-06-25
CY2017046I2 (el) 2018-12-12
NZ536757A (en) 2006-06-30
EP1504035B3 (en) 2017-12-20
DE60331910D1 (de) 2010-05-12
ECSP045470A (es) 2005-01-28
HUS1700055I1 (hu) 2018-07-30
EP1504035B1 (en) 2010-03-31
CY2017045I1 (el) 2019-11-27
US20030235869A1 (en) 2003-12-25
NO20044742L (no) 2004-12-22
EP1504035A2 (en) 2005-02-09
NL300920I1 (enExample) 2018-01-03
SG161744A1 (en) 2010-06-29
KR101156796B1 (ko) 2012-06-21
IL164923A0 (en) 2005-12-18
JP2006506955A (ja) 2006-03-02
WO2003093320A2 (en) 2003-11-13
JP2013230158A (ja) 2013-11-14
EP1504035B8 (en) 2018-02-28
LUC00057I2 (enExample) 2018-02-26
US20070059307A1 (en) 2007-03-15
LTPA2017044I1 (lt) 2018-01-10
MXPA04010787A (es) 2005-03-07
GB0210121D0 (en) 2002-06-12
NO2017068I1 (no) 2017-12-21
JP5377173B2 (ja) 2013-12-25

Similar Documents

Publication Publication Date Title
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
IS7173A (is) Líffræðilegar afurðir
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2004032857A3 (en) Antibody therapy